3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
4
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
3
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Hodgkin Disease
1
Burkitt Lymphoma
1
Interventions
fludarabine phosphate
38
Peripheral Blood Stem Cell Transplantation
35
Whole-Body Irradiation
30
Mycophenolic Acid
29
Cyclophosphamide
27
Tacrolimus
21
Cyclosporine
20
Busulfan
17
Antilymphocyte Serum
14
Methotrexate
13
Melphalan
12
Sirolimus
9
Radiotherapy
8
Filgrastim
8
Etoposide
8
Cyclosporins
8
Cord Blood Stem Cell Transplantation
6
Transplantation
5
Methylprednisolone
5
Bortezomib
5
sargramostim
4
Therapeutics
4
Everolimus
4
Epoetin Alfa
4
Cytarabine
4
Carboplatin
4
thymoglobulin
3
fludarabine
3
Thiotepa
3
Rituximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
acalabrutinib
×
Plasma cell
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts